On August 4, Waters rose 6.54% in regular trading, reaching $397.93 per share with turnover of $370 million. The rally was driven by the company's pre-market release of second-quarter results that topped Wall Street estimates on all key metrics, coupled with a full-year guidance raise.

Specifically, Waters reported Q2 adjusted EPS of $3.05, beating the consensus estimate of $3.01 by 1.33%, representing a 3.39% year-over-year increase from $2.95 in the prior-year period. Revenue came in at $1.645 billion versus the $1.623 billion estimate. More importantly, the company raised its full-year outlook, now expecting adjusted EPS of $14.45 to $14.65 and revenue of $64.15 billion to $64.76 billion, both above prior market consensus of $14.52 EPS.

Management cited broadening end-market recovery and better-than-expected integration progress of the Becton Dickinson Biosciences and Diagnostic Solutions acquisition, completed in February, as key factors behind the upgraded outlook. RBC Capital had previously noted the acquired BD assets were under-managed rather than structurally weak, suggesting significant turnaround potential under Waters' management.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)